Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Radient Technologies Inc V.RTI.H

Alternate Symbol(s):  RDDTF

Radient Technologies Inc. is a science-based company. The Company is a commercial manufacturer of cannabinoid-based formulations, ingredients, and products. The principal activities of the Company and its subsidiaries are engaged in research, development, and commercialization of an efficient and environmentally responsible technology for the extraction, isolation, and purification of soluble... see more

TSXV:RTI.H - Post Discussion

Radient Technologies Inc > RTI PARTICIPATE IN MED CANNABIS STUDY BY UNIVERSITY HEALTH .
View:
Post by Humanist on Jul 17, 2020 8:21am

RTI PARTICIPATE IN MED CANNABIS STUDY BY UNIVERSITY HEALTH .

Radient Technologies Inc. Announces Participation in a Medical Cannabis Study Led by the University Health Network in Partnership with Shoppers Drug Mart

July 17, 2020 07:30 ET | Source: Radient Technologies Inc

EDMONTON, Alberta, July 17, 2020 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a manufacturer of high quality cannabinoid-based formulations and products, is pleased to announce that bioU products by Radient will be available to patients in the recently announced University Health Networks’ (“UHN”)  Medical Cannabis Real-World Evidence Study (“MC-RWE Study”) in partnership with Medical Cannabis by Shoppers.  The first-of-its-kind study will involve a nation-wide clinical trial to examine the effects of medical cannabis on pain, sleep and anxiety issues.

Radient developed the bioU brand exclusively for Medical Cannabis by Shoppers and the products have been formulated to meet the highest levels of quality, consistency, and stability.  All three oral spray formulations currently available on the Medical Cannabis by Shoppers site will be available to patients enrolled in the MC-RWE Study, providing patients with a variety of options in THC and CBD products in a convenient and standard dose format.  As part of the study, all bioU products have undergone additional testing, with results registered on TruTrace Technologies software platform and integrated with the Medical Cannabis by Shoppers.

“Radient strongly believes that consistency, safety and standardization are key elements for all medical products, and are excited to partner with UHN, Shoppers and TruTrace on this groundbreaking study,” said Denis Taschuk, CEO of Radient Technologies.  “Providing patients and medical professionals with trusted products that deliver repeatable results is a crucial step in having cannabis incorporated into medical treatments and is at the heart of all Radient products.  Shoppers is creating a standard for medical cannabis, which along with the data from these clinical trials, will increase the confidence of both doctors and patients in using cannabis for medical purposes.”

About the UHN MC-RWE Study
Led by UHN's Dr. Hance Clarke, the observational study is targeting a minimum of 2,000 patients who will be followed over a 24-week period.  Enrolled patients will have access to certain fully verified products on the Medical Cannabis by Shoppers platform, which have been tested for detailed cannabinoid and terpene profiles.   Read more about the study here.
About Radient
Comment by McStockBigMac on Jul 17, 2020 8:59am
Min of 2000 patient for 24 -weeks getting ibio for the full 24 weeks. That's 2 years of guaranteed sales.
Comment by McStockBigMac on Jul 17, 2020 9:02am
I mean 6 months of sales
Comment by AaronEggs on Jul 17, 2020 9:07am
Everyone with oil on the site will participate so those 2000 patients can use any oil, this is a nothing burger 
Comment by bbuddwisserr104 on Jul 17, 2020 9:55am
haven't heard of any one else approved by third party lab yet rti has exclusive shoppers products for a reason  iam sure its all been in the works for a year or more to conduct a study like this leaving my marbles in the rti game till november longer if i see real progress
Comment by lscfa on Jul 17, 2020 2:54pm
One of many..... We are proud of our accomplishments and grateful to our client/partners at: Aphria, Aurora Cannabis, Avicanna, Inc., CanniMed, Dosecann Solutions, MediPharm Labs, Organigram, Radient Technologies, The Flowr Corporation The Valens Company, WeedMD Rx Inc./Starseed Medicinal Inc. and Zenabis Global, as well our laboratory partners at Sigma Analytical, Anandia Labs and High North.  ...more  
Comment by AaronEggs on Jul 17, 2020 3:25pm
Been sniffing too much co2 over at labs and vlns 
Comment by Chef999 on Jul 17, 2020 3:53pm
A great many parmaceutical companies made, and are still making, billions of dollars selling opiods to treat pain. If a safe, natural, non adictive, non lethal alternative is proven effective there will be PLENTY of money to go around! The cream of the crop, however, will rise to the top.  If thats a nothing burger I'd hate to see your version of a Big Mac!!
Comment by SeanPrice on Jul 17, 2020 4:41pm
Don't worry. ScrambledEggs is paid to post non stop, not to make sense. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities